# DrugDiscovery.Studio — Scientific Documentation & User Guide

Autonomous Biomedical AI Discovery & Multi-Hop Causal Hypothesis Synthesis

---

## 1. Quick Start Guide & Discovery Workflow

DrugDiscovery.Studio accelerates early-stage target de-risking and drug repurposing by solving the **literature island problem**.

### 5-Step Rapid Discovery Protocol:
1. **Define Concept A (Input Modality / Compound):** Small molecule, peptide, antibody, approved drug, or novel candidate entity (e.g. *Semaglutide*, *Olaparib*, *Metformin*, *Lenalidomide*).
2. **Define Concept C (Indication / Target Phenotype):** Disease indication, oncology subtype, or pathological state (e.g. *Alzheimer's Disease*, *Triple-Negative Breast Cancer*, *Glioblastoma*).
3. **Traverse Multi-Hop Topological Bridges ($B$-Terms):** The graph engine queries 13.1M+ empirical co-occurrence edges across 38.2M PubMed papers to identify intermediate biological bridges (kinases, receptors, transcription factors).
4. **Autonomous AI Mechanism Synthesis:** Frontier AI cross-evaluates literature evidence, screens for toxicology liabilities (hERG, liver, BBB), and formats a testable biological hypothesis.
5. **Compile & Export IND Research Dossiers:** Log findings to your *Translational Hypothesis Ledger* and export formal PDF/Word dossiers with suggested in-vitro validation protocols.

---

## 2. Scientific Methodology & Causal Graph Theory

### The Modernized Swanson Literature-Based Discovery (LBD) Paradigm
The platform mathematically identifies undiscovered linkages across disconnected literature domains:

$$	ext{Bridge Condition: } A \cap B \neq \emptyset \quad \wedge \quad B \cap C \neq \emptyset \quad \wedge \quad A \cap C = \emptyset$$

If literature sets show that Concept $A$ interacts with intermediate entity $B$, and separate literature proves that $B$ modulates disease $C$, but $A$ and $C$ have zero direct joint publications, then $A \rightarrow B \rightarrow C$ forms a novel, unstudied therapeutic pathway.

### B-Term Scoring & Gap Density
Intermediate entities are ranked by a multi-parametric score balancing topological connectivity and therapeutic novelty:
* **Empirical Association Weight ($W_{AB}, W_{BC}$):** Pointwise mutual information (PMI) and co-occurrence counts extracted from PubMed abstracts.
* **Direct Co-Occurrence Penalty ($W_{AC}$):** Penalizes well-known existing combinations to surface uncrowded patent whitespace.
* **Biological Modality Filter:** Prioritizes targetable druggable classes (GPCRs, Kinases, E3 Ligases, Ion Channels, Transcription Factors) via ChEMBL & Open Targets ontologies.

---

## 3. Validated Translational Benchmarks & Case Studies

### Benchmark 1: Neuro-Metabolic Repurposing
* **Pathway:** Semaglutide $\rightarrow$ GLP-1R / NLRP3 $\rightarrow$ Early Alzheimer's Disease
* **Causal Mechanism:** Semaglutide crosses the BBB to engage microglial GLP-1 receptors, activating intracellular cAMP/PKA to shut down NLRP3 inflammasome assembly and attenuate neuroinflammatory synaptic pruning.
* **Validation:** EVOKE & EVOKE+ Phase III Global Clinical Trials.

### Benchmark 2: Immuno-Oncology Synergies
* **Pathway:** Olaparib $\rightarrow$ cGAS-STING Innate Immunity $\rightarrow$ Triple-Negative Breast Cancer (TNBC)
* **Causal Mechanism:** Olaparib-induced unresolved replication fork collapse forces double-stranded DNA into the cytosol, triggering the cGAS-STING-TBK1 axis to turn immunologically 'cold' triple-negative tumors into interferon-rich, checkpoint-responsive targets.
* **Validation:** Nature & Science Immunology Synergies.

### Benchmark 3: Targeted Protein Degradation (TPD)
* **Pathway:** Lenalidomide $\rightarrow$ CRL4-CRBN E3 Ligase Complex $\rightarrow$ Multiple Myeloma
* **Causal Mechanism:** Reprograms the substrate specificity of the CRL4-CRBN E3 ubiquitin ligase to selectively recruit and degrade previously 'undruggable' lymphoid transcription factors Ikaros (IKZF1) and Aiolos (IKZF3).
* **Validation:** FDA Approved Standard of Care & TPD Foundation.

---

## 4. Real-Time AI Safety, Toxicology & In-Vitro Assay Protocols

* **hERG Cardiotoxicity:** Flags potential $I_{Kr}$ potassium channel blockade risks associated with QT prolongation.
* **Hepatotoxicity & DILI:** Screens for CYP450 reactive metabolite formation, mitochondrial toxicity, and liver injury risks.
* **BBB Permeability:** Computes CNS MPO scores and passive membrane diffusion for neurological targets.
* **Suggested In-Vitro Assays:** Target engagement (CETSA, SPR, NanoBRET), functional phosphorylation readouts, qPCR, and cell viability IC50 endpoints.

---

## 5. Translational Hypothesis Ledger & IND Dossiers

The **Translational Hypothesis Ledger** tracks every graph traversal and intermediate bridge inspection with exact PubMed citation provenance. Teams can export investigations into formal PDF, Word, or Markdown dossiers ready for grant proposals and FDA IND Pre-Meeting packages.

---

## 6. Enterprise Data Sovereignty & Zero-Retention

* **Zero-Retention Policy:** Proprietary input targets and compounds are never logged, stored in shared caches, or used to train public models.
* **Single-Tenant VPC Deployments:** Available on AWS, GCP, and Azure with dedicated KMS encryption keys.
* **SOC2 & HIPAA Compliant:** TLS 1.3 encryption across all discovery endpoints.
